## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applican	t:	§	
	SOREQ Hermona et al	<i>\$</i> \$	
Serial No.:	10/585,695	§ §	
Filed:	August 20, 2008	§ §	Group Art Unit:
For:Compound	ds, Pharmaceutical Compositions And Therapeutic Methods Of Preventing And Treating Diseases And Disorders Associated With Amyloid Fibril Formation	\$\times\tau \tau \tau \tau \tau \tau \tau \tau	Attorney Docket: 30394
Examiner:		§	
Mail Stop Amer Commissioner f P.O. Box 1450 Alexandria, VA	or Patents		
	INFORMATION DISCLOSURE STATEMENT	Ω	
Sir:			
examination of submitted in cor	d is a PTO Form 1449 which lists citations which may be rethe above identified application. Also enclosed are copies of appliance with the duty of disclosure defined in 37 CFR 1.56. The fofficial record in this application.	the re	eferences cited. These are
The und	lersigned states:		
in any communi	That each item of information contained in the information disc cation from a foreign patent office in a counterpart foreign applitude the filing of the information disclosure statement; or		
communication person signing thing the contraction of the communication of the communication discussion of the communication of the com	That no item of information contained in the information disclo from a foreign patent office in a counterpart foreign application he certification after making reasonable inquiry, no item of infollosure statement was known to any individual designated in 37 the filing of the information disclosure statement.	, and, rmatic	to the knowledge of the on contained in the
	Please charge the fee of \$180 set forth in 37 CFR 1.17 (p) to De	posit	Account 501407.
representation th	Formation Disclosure Statement submitted pursuant to 37 CFR nat a search has been made, that additional matter which is may not exist, or that the information disclosed constitutes prior	aterial	to the examination of this
	Respectfully s	ubmit	ted,
	/Martin D. Mo	yniha	n/
	Martin D. Mo Registration N		

Dated: November 30, 2008